-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$5.6775.54% Upside
Relmada Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Relmada Therapeutics, Inc.?
Relmada Therapeutics, Inc. has been rated by research analysts at Goldman Sachs, Jefferies, Oppenheimer in the past 90 days.